Results 21 to 30 of about 49,553 (292)
Cancer Biology & Medicine, 2023 Objective: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. CD8+ T cells, cancer stem cells (CSCs), and tumor budding (TB) have been significantly correlated with the outcome of patients with PDAC, but the correlations have been ...
Tianxing Zhou +11 more
doaj +1 more source
DUSP2 regulates extracellular vesicle-VEGF-C secretion and pancreatic cancer early dissemination
Journal of Extracellular Vesicles, 2020 Early dissemination is a unique characteristic and a detrimental process of pancreatic ductal adenocarcinoma (PDAC); however, the underlying mechanism remains largely unknown.
Chu-An Wang +10 more
doaj +1 more source
International Journal of Hyperthermia, 2021 Purpose This study aimed to compare the survival benefits between high-intensity focused ultrasound (HIFU) combined with chemotherapy and chemotherapy alone in patients with unresectable pancreatic ductal adenocarcinoma (PDAC).
Jing Guo +4 more
doaj +1 more source
Loss of FGFR4 promotes the malignant phenotype of PDAC [PDF]
, 2022 Transcriptomic analyses of pancreatic ductal adenocarcinoma (PDAC) have identified two major epithelial subtypes with distinct biology and clinical behaviours.
Bria, Emilio
core +3 more sources
Metabolism remodeling in pancreatic ductal adenocarcinoma
Cell Stress, 2019 Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of death of patients with malignant cancers by 2030. Current options of PDAC treatment are limited and the five-year survival rate is less than 8%, leading to an ...
Jin-Tao Li +3 more
doaj +1 more source
, 2023 Dataset of PDAC patients (in rows) including survival, histological, analgetic and molecular data (in columns)
Josef Srovnal (5190059)
core +1 more source
nunonene/Ensemble-learning-for-PDAC-early-detection: PDAC early detection
, 2022 Code for replicating main results in Nene et al (2021)
Nuno Rocha Nene, Ph.D.
core +1 more source
International Journal of Nanomedicine, 2021 Julian Palzer,1,2 Benedikt Mues,2 Richard Goerg,1,2 Merel Aberle,3 Sander S Rensen,3 Steven WM Olde Damink,1,3 Rianne DW Vaes,3 Thorsten Cramer,1,3 Thomas Schmitz-Rode,2 Ulf P Neumann,1,3 Ioana Slabu,2 Anjali A Roeth1,3 1Department of General, Visceral ...
Palzer J +11 more
doaj
Elevated microRNA expression could be diagnostic biomarker for PDAC
, 2020 Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of PCa with 2-9% 5-year survival rate. PDAC is the most lethal malignancy worldwide and hence the molecular mechanisms, which are linked to the aggressive features, should be ...
Uysal Onganer, P. +4 more
core +1 more source
ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC) [PDF]
, 2014 Pancreatic ductal adenocarcinoma (PDAC) has one of the worst survival rates of all cancers. ANO1 (TMEM16A) is a recently identified Ca2+-activated Cl- channel (CaCC) that is upregulated in several tumors. Although ANO1 was subject to extensive studies in
Sauter, Daniel Rafael Peter +9 more
core +1 more source